title: Soluble interleukin-6 receptor is a serum biomarker for the response of esophageal carcinoma to neoadjuvant chemoradiotherapy.
abstract: Preoperative chemoradiotherapy has been shown to improve the outcome of patients with esophageal cancer, but because response to this therapy varies, it is desirable to identify in advance individuals who would be unlikely to benefit, in order to avoid unnecessary adverse drug effects. The serum profiles of 84 cytokines and related proteins were determined in 37 patients with esophageal squamous cell carcinoma who received identical neoadjuvant preoperative chemoradiotherapy regimens and underwent surgical resection. Histological response to this therapy was assessed in surgically resected specimens. The serum soluble interleukin-6 receptor (sIL6R) level was significantly higher in 30 patients who failed to achieve a histological complete response (P = 0.005). Multivariate analysis revealed that the increased level of sIL6R was one of several significant independent predictors of an unfavorable outcome (hazard ratio, 2.87; P = 0.017). The increased level of this cytokine in patients who did not obtain a complete response was reproducibly observed in an independent cohort of 34 patients. Esophageal squamous cell carcinoma patients with an increased serum level of sIL6R are predicted to respond poorly to preoperative chemoradiotherapy, therefore, their exclusion from this treatment may be considered. Persistent systemic inflammation is implicated as a possible mechanism of resistance to this therapy.
authors: Division of Chemotherapy and Clinical Research, National Cancer Center Research Institute, Tokyo, Japan.
authors: Yosuke
authors: Y
authors: Makuuchi
authors: Kazufumi
authors: K
authors: Honda
authors: Yoshiaki
authors: Y
authors: Osaka
authors: Ken
authors: K
authors: Kato
authors: Takashi
authors: T
authors: Kojima
authors: Hiroyuki
authors: H
authors: Daiko
authors: Hiroyasu
authors: H
authors: Igaki
authors: Yoshinori
authors: Y
authors: Ito
authors: Sumito
authors: S
authors: Hoshino
authors: Shingo
authors: S
authors: Tachibana
authors: Takafumi
authors: T
authors: Watanabe
authors: Koh
authors: K
authors: Furuta
authors: Shigeki
authors: S
authors: Sekine
authors: Tomoko
authors: T
authors: Umaki
authors: Yukio
authors: Y
authors: Watabe
authors: Nami
authors: N
authors: Miura
authors: Masaya
authors: M
authors: Ono
authors: Akihiko
authors: A
authors: Tsuchida
authors: Tesshi
authors: T
authors: Yamada
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000097:blood*; D002294:Carcinoma, Squamous Cell / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D059248:Chemoradiotherapy / Q000379:methods; D015331:Cohort Studies; D004938:Esophageal Neoplasms / Q000097:blood* / Q000473:pathology / Q000628:therapy*; D000077277:Esophageal Squamous Cell Carcinoma; D005260:Female; D006801:Humans; D007249:Inflammation / Q000097:blood / Q000473:pathology; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D019947:Receptors, Interleukin-6 / Q000097:blood*; D012189:Retrospective Studies
chemical_list: D014408:Biomarkers, Tumor; D019947:Receptors, Interleukin-6
references: Eur J Cancer. 2001 Oct;37 Suppl 8:S4-66
references: 11602373
references: FASEB J. 2001 Jan;15(1):43-58
references: 11149892
references: Cancer Res. 2005 Nov 15;65(22):10613-22
references: 16288055
references: J Interferon Cytokine Res. 1996 Dec;16(12):1001-6
references: 8974001
references: J Clin Oncol. 2007 Sep 10;25(26):4110-7
references: 17827461
references: J Biol Chem. 2011 Dec 16;286(50):42959-70
references: 21990364
references: Oncogene. 2001 Jan 11;20(2):198-208
references: 11313947
references: J Clin Oncol. 2008 Mar 1;26(7):1086-92
references: 18309943
references: J Surg Oncol. 2003 Aug;83(4):248-52
references: 12884238
references: Cancer Cell. 2006 Aug;10(2):99-111
references: 16904609
references: Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):725-34
references: 18164836
references: Surgery. 2003 Jan;133(1):24-31
references: 12563234
references: J Clin Oncol. 2005 Jul 1;23(19):4330-7
references: 15781882
references: J Cell Biol. 1998 Mar 23;140(6):1383-93
references: 9508771
references: Gastroenterology. 2005 Jan;128(1):51-62
references: 15633123
references: Gut. 2004 Jul;53(7):925-30
references: 15194636
references: Int J Cancer. 2008 Oct 15;123(8):1935-40
references: 18688852
references: J Clin Invest. 2011 Sep;121(9):3375-83
references: 21881215
references: Cancer Res. 2012 Aug 15;72(16):3967-76
references: 22700877
references: Lancet Oncol. 2005 Sep;6(9):659-68
references: 16129366
references: Ann Thorac Surg. 2009 Feb;87(2):392-8; discussion 398-9
references: 19161745
references: Eur J Cancer. 2002 Jan;38(2):300-13
references: 11803146
references: J Surg Oncol. 2011 Jan 1;103(1):62-8
references: 21031427
references: Am J Public Health. 1996 May;86(5):726-8
references: 8629727
references: J Thorac Oncol. 2011 Apr;6(4):699-706
references: 21325979
references: Int J Clin Oncol. 2019 Jan;24(1):60-67
references: 30109544
references: Clin Cancer Res. 2008 Sep 1;14(17):5348-56
references: 18765526
references: J Natl Cancer Inst. 2007 Aug 15;99(16):1257-69
references: 17686824
references: Oncol Rep. 2004 Nov;12(5):1121-6
references: 15492803
references: Anticancer Res. 2011 Jan;31(1):67-75
references: 21273582
references: Ann Oncol. 2004 Jun;15(6):947-54
references: 15151953
references: Int J Radiat Biol. 2009 May;85(5):421-31
references: 19437244
references: Cancer Sci. 2013 Aug;104(8):1045-51
references: 23648090
references: J Gastrointest Surg. 2010 Mar;14(3):462-9
references: 19937473
references: Oncogene. 2003 Oct 30;22(49):7809-18
references: 14586407
references: N Engl J Med. 2012 May 31;366(22):2074-84
references: 22646630
references: Cancer. 2001 Aug 1;92(3):663-9
references: 11505413